Lapaquistat acetate and lipid-lowering therapy
TAK-475/EC304
Phase 3 small_molecule completed
Quick answer
Lapaquistat acetate and lipid-lowering therapy for Type 2 Diabetes is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Type 2 Diabetes
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed